X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Nicotine polacrilex lozenges are an important addition to our current offering of nicotine replacement therapy including nicotine transdermal system patches, sold as Habitrol® brand and various store brands.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Nicotine Polacrilex-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
Details:
U.S. Food and Drug Administration approved OTC, nicotine coated mint lozenges, works by reducing withdrawal symptoms in consumers who are trying to quit smoking.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Nicorette-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
CVSI-007 contains nicotine and cannabidiol which supports the cessation of smokeless tobacco use and addiction, if approved it'll be the first and only treatment for smokeless tobacco addiction.
Lead Product(s): Nicotine,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: CVSI-007
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
The Series A proceeds will be used by Qnovia to advance its NRT drug candidate RespiRx (drud device combination having nicotine) through an IND submission with the FDA and begin human clinical trials in 2023.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: RespiRx
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blue Ledge Capital
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 28, 2022
Details:
With dozens of patent allowing it to control VLN (nicotine) biosynthesis in tobacco plant, Company has developed proprietary reduced nicotine content tobacco plant and cigarette, which become FDA’s Comprehensive Plan to address widespread death and disease caused by smoking.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: VLN
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Company launching Phase II/III clinical trial of NFL-101, most innovative natural drug candidate in an advanced clinical development phase, could be first-line solution providing real support for people looking to stop smoking and for the treatment of their addiction.
Lead Product(s): Tobacco Leaf Protein,Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details:
The partnership between NFL Biosciences and Diverchim will involve manufacturing the active ingredient for NFL-101 for its use in additional clinical trials beyond the current CESTO II study (Phase II/III).
Lead Product(s): Tobacco Leaf Protein,Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Diverchim S.A.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2021
Details:
NFL-101, a nicotine-free botanical drug candidate comprising natural proteins extracted from tobacco leaves, focused primarily on smoking cessation.
Lead Product(s): Tobacco Leaf Protein,Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
Details:
NFL-101 is natural nicotine-free product, extracted from standard tobacco leaves, is protected by two patent families. This trial’s aims to make NFL-101 available to the 780 million smokers that the World Health Organization estimates want to stop smoking.
Lead Product(s): Tobacco Leaf Protein,Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Philip Morris International
Deal Size: $820.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 15, 2021
Details:
Through the acquisition, PMI will build its overall platform of R&D and manufacturing expertise in nicotine and beyond nicotine product areas through the addition of Fertin’s strong capabilities and skilled workforce.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Philip Morris International
Deal Size: $820.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 01, 2021
Details:
Nfl Biosciences' lead drug, NFL-101, is a standardized extract of tobacco leaf, contains only minute amounts of nicotine and natural tobacco leaf proteins.
Lead Product(s): Tobacco Leaf Protein,Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
